Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker TVGN, is a clinical-stage biopharmaceutical company focused on developing T-cell-based immunotherapies targeting infectious diseases and oncology. The company completed its SPAC merger and became publicly listed, filing its first annual report on Form 10-K with the SEC on April 17, 2023, under accession number 0001410578-23-000698. Operating within the biotechnology and life sciences sector, Tevogen Bio is positioned around its proprietary TVGN 489 platform, which seeks to harness cytotoxic T lymphocytes as precision therapeutic agents. Visit SpacDesk and sign up for full data, filings history, and real-time alerts on TVGN and hundreds of other SPAC-related companies.